載入...

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

BACKGROUND. This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first‐line treatment in real‐world practi...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Yao, Zong‐Han, Liao, Wei‐Yu, Ho, Chao‐Chi, Chen, Kuan‐Yu, Shih, Jin‐Yuan, Chen, Jin‐Shing, Lin, Zhong‐Zhe, Lin, Chia‐Chi, Chih‐Hsin Yang, James, Yu, Chong‐Jen
格式: Artigo
語言:Inglês
出版: AlphaMed Press 2017
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599189/
https://ncbi.nlm.nih.gov/pubmed/28507206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0331
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!